Latest Breaking News On - Shreeram aradhye - Page 5 : comparemela.com

Novartis shares positive phase 3 results for Scemblix in chronic myeloid leukaemia

Novartis shares positive phase 3 results for Scemblix in chronic myeloid leukaemia
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

United statesShreeram aradhyeNovarti scemblix

Asciminib Provides MMR Benefits vs SOC TKIs in Newly Diagnosed Ph+ CML

Asciminib demonstrated a favorable safety profile and induced statistically significant and clinically meaningful major molecular response benefits vs standard-of-care TKIs in patients with newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

South australiaUnited statesAsciminib scemblixShreeram aradhyeTim hughesNovartis scemblixAustralian health medical research instituteSouth australian healthMedical research instituteHematologic oncologyChronic myeloid leukemiaPhase 3 asc4first trial

Novartis reports success in phase 3 trial of drug for rare kidney disease

Novartis reports positive topline results from a Phase 3 trial of iptacopan, a drug to treat a rare kidney disease, C3 glomerulopathy.

Shreeram aradhye3 glomerulopathyKidney diseaseTopline resultsPhase 3 trialFda approval

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Ad hoc announcement pursuant to Art. 53 LR Phase III APPEAR-C3G study met its primary endpoint, demonstrating superiority of iptacopan vs. placebo in proteinuria reduction at six-month analysis1;.

Czech republicUnited statesSloan simpsonSatoshi sugimotoParag mahantiIsabella zinckJonathan grahamJulie masowSamir shahRichard jarvisShreeram aradhyeZain iqbalNicole zinsli sommImke kappesMarlena abdinoorMichael meo

Novartis Pharma AG: Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)

Novartis Pharma AG: Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and statistically significant proteinuria reduction in patients with C3 glomerulopathy (C3G)
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Czech republicUnited statesSamir shahJonathan grahamIsabella zinckSatoshi sugimotoRichard jarvisShreeram aradhyeStefan klotterZain iqbalSloan simpsonImke kappesNicole zinsli sommMichael meoJulie masowParag mahanti